INTRODUCTION
The integral membrane protein BACE-1 (Beta Amyloid Cleaving Enzyme 1) is the b-secretase that cleaves the amyloid precursor protein (APP) (1±5), producing a soluble APP b fragment (sAPPb) and a C-terminal membraneassociated peptide (C99). Further proteolytic cleavage of C99 by a g-secretase, tentatively identi®ed as a multimeric complex formed by presenilins, nicastrin and other proteins (6±8), produces a cytosolic fragment (APP intracellular domain, AICD) and the amphypatic b-amyloid peptide (A-b). The latter accumulates in the brain of Alzheimer's disease (AD) patients in the form of amyloid plaques and is thought to be directly or indirectly responsible for the ensuing neurodegeneration (9) . Given this premise, BACE-1 expression is expected to play a fundamental role in the control of A-b production, and thus in the etiopathogenesis of AD. Indeed, experimental overexpression of BACE-1 increases the production of A-b in both cell lines (1±3) and transgenic mice (10) . Moreover, an increase in b-secretase activity and BACE-1 protein was observed in the brain of AD patients (11±14).
The control of BACE-1 expression could occur at transcriptional, as well as post-transcriptional level. The BACE-1 promoter is currently under investigation and a recent publication reports an initial characterization of the corresponding rat sequence (15) . However, there is also evidence that post-transcriptional events might affect expression. For instance, while in neurons the amount of A-b produced is related to BACE-1 expression levels, in astrocytes (16, 17) , as well as in other tissues (1±3), a poor correlation between BACE-1 transcript and b-secretase activity was found. This is the case for exocrine pancreas, where the extremely high levels of BACE-1 transcript are not re¯ected by the presence of either the protein or the activity (1, 18) . A hypothesis to explain this discrepancy is a mechanism involving an inhibition of translation initiation (19) . Recently, however, BACE-1 protein has been detected in exocrine pancreas, even though it is cleaved by an unknown protease (20) . In any event, it should be noted that, while the amounts of proteolized BACE-1 in pancreas and liver are comparable (20) , the levels of mRNA are several-fold higher in pancreatic tissue (1) . Another indication in support of a translational control of BACE-1 expression comes from the evidence that changes in BACE-1 mRNA have never been observed in the brains of AD patients, despite the increase in protein and/or activity (21±23).
Translation can be controlled by structures that are present in the mRNA untranslated regions such as internal ribosome entry site (IRES) (24, 25) or iron responsive elements (IRE) (26) . In addition, other mRNA features can contribute to the translational control of gene expression. Among them upstream AUGs (uAUGs) and upstream open reading frames (uORFs) are thought to down-regulate the ef®ciency of translation initiation of the main ORF (27, 28) and were shown to repress the translation of important proteins such as TPO (29) , connexin 41 (30) , huntingtin (31), the transcription factors GCN4 (32) and ATF4 (33) , as well as other proteins (34±36).
In the present paper we investigate the involvement of these mechanisms in the control of BACE-1 translation and the possibility that this control might operate in astrocytes upon their activation. The possible involvement of this mechanism in the pathogenesis of AD is discussed.
MATERIALS AND METHODS

Materials
Restriction and modi®cation enzymes for DNA cloning were from New England Biolabs; DNA oligonucleotides from Primm; [a-32 P]CTP from Amersham; reagents and media for cell culture from Cambrex. RNA extraction was performed with the RNeasy midi kit (Qiagen). Human tissues were provided by F.Bertuzzi (Islet Transplantation Unit) and M.Losa (Neurosurgery Unit), San Raffaele Scienti®c Institute, Milano, Italy. Human brain total RNA was from Clontech. The EST clone (GenBank accession number BG833894) encoding the full length BACE-1 transcript leader from Sus scrofa cDNA, was obtained from Children's Hospital Oakland-BACPAC Resources, Oakland, CA. The MVA-T7pol vaccinia virus was provided by Dr Gerd Sutter, Institute of Molecular Virology, GSF-National Research Centre for Environment and Health, Oberschleissheim, Germany.
Cloning of BACE-1 transcript leaders
Reverse transcription (primer, CCG TGG GCA GGC AGC AC) and ampli®cation (sense, AGT CCC ATG GAG CTG CGA GCC GCG AGC T; antisense, CCA TCC ACA GCA GGA GCC AGG GCA) of BACE-1 from total RNA from exocrine pancreas, brain temporal cortex or SK-N-BE cells was performed with the One-Step RT±PCR kit (Qiagen). The same sense oligo was used with a nested antisense oligo (TTG GGC CAT GGT GGG CCC CGG CCT T) for reampli®cation. The PCR product was inserted into the pGEM-T vector (Promega) obtaining pGEMT-BACE1-5¢y (short BACE-1 transcript leader). To obtain the long BACE-1 transcript leader, the BsrGI fragment from an EST clone (GenBank accession number AL544727, Invitrogen) was cloned into the Acc65I site of pBluescript-KS(+) (Stratagene), to obtain pBS-Bace1-Est, and then ampli®ed by PCR (sense, AGT CCC ATG GAG CTG CGA GCC GCG AGC TGG ATT A; antisense, TTG GGC CAT GGT GGG CCC CGG CCT T), digested with NcoI and cloned into pGEMT-BACE1-5¢y after removal of the NcoI fragment. The new plasmid was named pGEMD-BACE1-5¢x.
Cloning of expression vectors and site-directed mutagenesis
The dicistronic pBRL-Nco empty vector was prepared from pBATmod2RL-IRES-LUC+ (37) by removal of the EMCV IRES (NcoI±BamHI digestion, followed by T4 DNA polymerase treatment before ligation). For the preparation of the bi-monocistronic pBRm2L-Nco empty vector, pBATmod2-RL-mono-Nco-LUC+ (D.De Pietri Tonelli, unpublished) was opened with BglII and SalI, and a synthetic double-strand oligo with a T7 terminator followed by a T7 promoter was inserted (sense, GAT CTA ACC CCT TGG GGC CTC TAA ACG GGT CTT GAG GGG TTT TTT GCA GAT CTC GAG GCC TTA ATA CGA CTC ACT ATA GGG; antisense, TCG ACC CTA TAG TGA GTC GTA TTA AGG CCT CGA GAT CTG CAA AAA ACC CCT CAA GAC CCG TTT AGA GGC CCC AAG GGG TTA).
BACE-1 fragments were extracted with NcoI from pGEMD-BACE1-5¢x and pGEMT-BACE1-5¢y and ligated into the NcoI site of pBRL-Nco or pBRm2L-Nco to obtain dicistronic pBRL-B1x, pBRL-B1y, pBRL-B1xas and pBRLB1yas, and bi-monocistronic pBRm2L-B1x and pBRm2L-B1y. pBRm2L-B1uORF1 and pBRm2L-uPEP were prepared by inserting into pBRm2L-Nco the fragments obtained by PCR ampli®cation of pGEMD-BACE1-5¢x (sense, AGT CCC ATG GAG CTG CGA GCC GCG AGC TGG ATT A; antisense for B1uORF, AGG GGC GGC CAT GGC GGG CCG GT; antisense for uPEP, ACG TCC GCG GAG CTG CGA GCC GCG AGC T). The ®rst fragment was inserted using NcoI digestion. The second was cleaved with SmaI and SacII, and inserted into an NcoI-(blunt with Mung Bean Nuclease) and SacII-digested plasmid.
Single point mutations were generated with Pfu turbo polymerase (Stratagene) by PCR-based site directed mutagenesis with overlapping oligos (38) . pGEMD-BACE1x-mut1 was generated from pGEMD-BACE1-5¢x (sense, ACC GGC CCG CCT TGC CCG CCC CT; antisense, AGG GGC GGG CAA GGC GGG CCG GT); pGEMD-BACE1x-mut2 from pGEMD-BACE1x-mut1 (sense, GTG CCG TTG TAG CGG GCT CCG GA; antisense, TCC GGA GCC CGC TAC AAC GGC AC). pGEMD-BACE1x-mut3 from pGEMD-BACE1x-mut2 (sense, CGA GCT GGA TTT TGG TGG CCT GA; antisense, TCA GGC CAC CAA AAT CCA GCT CG). DNA fragments were digested with NcoI and cloned in pBRm2L-Nco.
RNase protection assay
The full-length 32 P-labeled riboprobe was prepared with the T7-SP6 in vitro transcription system (Promega) starting from SpeI-linearized pGEMD-BACE1-5¢x and puri®ed over an RNeasy mini spin column (Qiagen) according to the RNA clean-up protocol. Two shorter probes, utilized as size markers, were obtained following the same procedure but starting from BamHI (probe length 316 nt), or XmaIlinearized (probe length 241 nt) pGemT-BACE1-5¢y. The RNAse protection assay was performed with the RPA III kit (Ambion) according to the manufacturer's instructions with the following modi®cations: 15 mg of total RNA (from either human pancreas or brain) was incubated with the riboprobe (55 000 c.p.m.) overnight at 60°C, and then digested with a 1:100 dilution of the RNAse A/T1 mix. Protected fragments were separated in a 0.75 mm thick and 40 cm long 5% polyacrylamide gel, and revealed by either overnight exposure onto a phosphoimager screen (Molecular Dynamics) or 10 days of exposure onto an X-ray ®lm (Kodak).
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Cell culture and transfection
Cells were maintained as follows: U373-MG in Earle's Minimal Essential Medium (MEM) supplemented with 10% fetal calf serum (FCIII, Hyclone) and 1 mM sodium pyruvate; HeLa and SK-N-BE cells in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 5% FCIII and 10% Donor Horse Serum for HeLa or 15% FCIII, 1 mM sodium pyruvate and 1 mM non-essential amino acids for SK-N-BE. All media were supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM glutamine, and cells were cultured at 37°C in a humidi®ed 5% CO 2 atmosphere. Rat cortical astrocytes and hippocampal neurons were prepared according to McCarthy and De Vellis (39) and Ryan and Smith (40), respectively. After 10±15 days in culture, astrocytes were shaken (24 h, 220 r.p.m.) to remove microglia. Proliferating cells were plated the day before an experiment in order to reach about 70% con¯uence at the time of transfection. Cells were infected with the MVA-T7pol virus in MEM for 30 min at 37°C and then transfected for 6 h with plasmids carrying the DNA construct of interest. The transfection was performed with Superfect (Qiagen) according to the manufacturer's instructions. Astrocyte activation was obtained by a 24 h treatment with 10 ng/ml recombinant rat IL-1b and 30 ng/ml recombinant rat TNF-a.
Luciferase reporter assay
Fire¯y luciferase (Fluc) and Renilla luciferase (Rluc) activities were revealed with the Dual-Luciferase reporter assay system (Promega) and measured (20 s readings) using a PlateLumino double injector luminometer (Stratec) or a Victor3 plate reader (Perkin-Elmer). Four independent reactions were carried out for each experimental point.
Polysome analysis
Transfected HeLa cells were lysed with polysomal buffer (100 mM NaCl, 30 mM MgCl 2 , 10 mM Tris±HCl, 0.1% NP-40, 100 U/ml RNAsin, pH 7.5). Aliquots (100 ml:~10 OD) of the cleared lysate were overlayed onto a 7±50% w/v sucrose gradient (containing 50 mM Tris±acetate, 50 mM NH 4 Cl, 1 mM DTT, pH 7.5) and pelleted by ultracentrifugation in a SW41 rotor (39K, 160 min). Ten fractions (1 ml each) were collected from the top using a gradient collector with continuous monitoring at 254 nm. Total RNA from each fraction was obtained by proteinase K treatment followed by phenol/chloroform extraction. Fluc transcript levels were revealed by RT±PCR (SuperScript and Platinum Taq, Invitrogen) with oligo-dT priming followed by ampli®cation with gene speci®c oligos (sense, GCC TAA AGG TGT CGC TCT GCC T; antisense, GAA GAT GTT GGG GTG TTG GAG CA).
In vitro translation and mRNA decay
For in vitro translation the plasmids pZac-Bace1x-Luc+ and pZac-Bace1y-Luc+ were prepared by inserting into the SalI± NsiI digested pZac-Luc+ (37) the SalI±NsiI fragments of pBRm2L-B1x and pBRm2L-B1y, respectively. Synthesis of Fluc cRNA from PacI-or PstI-linearized pZac plasmids was obtained with the mMESSAGEmMACHINE kit (Ambion). Translation (0.3 mg of cRNA in 25 ml) was performed with the ReticLysate IVT kit (Ambion). For the decay assay, the radioactive cRNA was prepared with the Riboprobe in vitro transcription system (Promega) and puri®ed with the Rneasy spin column (Qiagen). The cRNA (~500 000 c.p.m.) was incubated in the translation reaction and puri®ed again at different time points before scintillation counting.
RESULTS
In order to clone the transcript leader of BACE-1 we performed an RT±PCR on total mRNA from human brain and pancreas. In our conditions, we did not get any ampli®-cation product from brain. However, in pancreas we obtained a band smaller than expected on the basis of the published sequence (accession number AF190725). Cloning and sequencing of the ampli®ed DNA revealed a putative alternative splice variant of the BACE-1 transcript leader. We submitted this shorter sequence to the GenBank database under the accession number AF324837. The same sequence was also ampli®ed from SK-N-BE cells. Figure 1 shows the alignment of the cDNA of the BACE-1 transcript leaders from various mammalian species and highlights the putative splicing sites. BACE-1 transcript leader is highly conserved, GC rich and contains several uAUGs and a uORF of 72 nt (60 nt in pig sequence). Although we did not map the actual donor±acceptor splice site (there are three possible combinations: ATTA..GCGG; ATT..AGCGG; AT..TAGCGG), it can be noticed that nucleotides around the splice sites are well conserved, making alternative splicing also likely in the other species analysed. Interestingly, the splicing event removes three out of four uAUGs.
Since we had isolated the short BACE-1 transcript leader from human exocrine pancreas and SK-N-BE cells, we then investigated whether this variant was also expressed in normal human brain. We performed an RNase protection assay with one riboprobe to quantify the relative amount of the two splice variants (Fig. 2A) . The long and the short transcript leaders were expected to generate protected fragments of 435 and 240 nt, respectively (Fig. 2B) . Total RNA (15 mg) from either human brain or exocrine pancreas were incubated with the same amount of 32 P-labelled riboprobe and digested with RNase. In brain tissue only the long form of the BACE-1 transcript leader was expressed, while in pancreas both forms were present at comparable levels (Fig. 2C) . The same ®nding was obtained with an antisense probe synthesized using the short transcript leader as template (data not shown).
We next decided to test whether the BACE-1 transcript leader was acting as an IRES element, thereby supporting cap-independent initiation of translation. Standard DNA transfection could not be used since a promoterless approach revealed the presence of a cryptic promoter in the transcript leader of BACE-1 (data not shown). For this reason the full-length or the spliced variant of BACE-1 leader, was inserted in the dicistronic plasmid pBRL-Nco between two reporter genes (37) . In this way the activity of the 3¢ cistron (Fluc) was normalized to the activity of the 5¢ cistron (Rluc) to account for variations in the ef®ciency of transfection. Each dicistronic construct, under the transcriptional control of a single T7 promoter, was transiently transfected in SK-N-BE or HeLa cells. Expression was driven by the MVA-T7pol vaccinia virus system, a strategy that allows the transcription of the gene of interest to occur solely in the cytosol (41). This system was chosen to avoid artefacts arising from nuclear events such as transcription via cryptic promoters or mRNA processing (37). We did not detect any signi®cant IRES activity with either transcript leaders (data not shown). However, our results leave open the possibility that IRES activity might be promoted by a`nuclear experience' of the transcript.
In order to investigate the effect of the BACE-1 transcript leader on cap-dependent translation, we prepared a series of bi-monocistronic plasmids (Fig. 3A) . These plasmids contain two independent transcriptional units under the control of two T7 promoters. The ®rst cassette generates a transcript containing the Rluc reporter gene, which was used to normalize for differences in transfection ef®ciency. The second cassette generates an mRNA with the Fluc gene preceded by either the long (pBRm2L-B1x) or the short (pBRm2L-B1y) BACE-1 transcript leader. These plasmids were transiently transfected by the MVA-T7pol system in the following cells: SK-N-BE (human neuroblastoma); U-373-MG (human astrocytoma); primary hippocampal neurons and cortical astrocytes from newborn rat; HeLa (human adenocarcinoma). Translation was quanti®ed as the ratio of the activities of the two reporter genes (Fluc/Rluc). Both the long and the short BACE-1 transcript leaders were less active (one to two orders of magnitude) than the empty vector pBRm2L-Nco in supporting translation initiation (Fig. 3B) [for quanti®cation, see also De Pietri Tonelli et al. (37) ]. The possibility that changes in transcript stability might account for such a difference was ruled out by evaluating the levels of Fluc transcripts by RT±PCR (Fig. 3B, inset) . Interestingly, the short form of BACE-1 leader, which lacks three out of four uAUGs, was 2±8-fold more active than the long form. To better evaluate the translation ef®ciency, we examined by polysome analysis the cytoplasmic distribution of Fluc mRNA in transfected cells. The result in Figure 3C shows that the control mRNA (from pBRm2L-Nco) was mostly present in the polysomal fractions of the gradient. In contrast, the majority of the mRNA from either pBRm2L-B1x In order to investigate whether the data obtained by transfection were affected by variations in mRNA stability, we performed experiments of in vitro translation also monitoring the mRNA decay rate. Translation driven by either BACE-1 leader in a rabbit reticulocyte translation assay was about two orders of magnitude lower than control (Fig. 4A) . Noticeably, the stability of all radioactively labelled transcripts was identical (Fig. 4B) .
To understand the relative contribution of the four uATGs in the translation repression, we performed an analysis of the context for translation initiation surrounding each uATG (27) with the NetStart program (42) . The prediction showed that the second uATG, which is positioned in a good Kozak context, is recognized by the ribosome with at least the same ef®ciency as the main ATG, while the other three uATGs are not in good contexts for translation initiation. To test this prediction, we mutated the second uATG of the long BACE-1 transcript leader (pBRm2L-B1x-mut1 plasmid) (Fig. 5A) . The transfection in SK-N-BE cells revealed that the activity of the mutant was~5-fold higher than the long BACE-1 leader (pBRm2L-B1x), but still lower than the short form (pBRm2L-B1y). Then, we mutated sequentially the other uATGs as described in Figure 5A , generating pBRm2L-B1x-mut2 and pBRm2L-B1x-mut3. The effect of these mutations was additive in overcoming the translational hurdle (Fig. 5B) .
According to this result, the second uATG exerts a prominent repression on translation. This might be accomplished by recruiting the ribosomal machinery for an abortive cycle of translation. To test this hypothesis, we generated the bi-monocistronic plasmid pBRm2L-B1x-uORF1, in which the second reporter gene (Fluc) is positioned immediately after the second uATG. As predicted, transfection in SK-N-BE and U-373-MG cells con®rmed that this uATG is ef®ciently recognized by the translation machinery (data not shown).
To see whether translational control of BACE-1 has relevance in physiopathological conditions, we used the activated astrocyte model. Astrocytes pretreated for 24 h with IL-1b (10 ng/ml) and TNF-a (30 ng/ml) or nothing were transfected for 4 h with bi-monocistronic plasmids using the MVA-T7pol system. In this way differences between expressions of the reporter genes can be attributed to variations in translation ef®ciency. Interestingly, Fluc translation driven by BACE-1 transcript leader, either long or short, was 4-fold higher in activated astrocytes, while translation of the empty construct pBRm2L-Nco was unaffected (Fig. 6) . In contrast, no changes in translation were observed when astrocytes were exposed to acute (2 h) stimulation with maximal concentration of physiological agonists such as glutamate, ATP and PGE 2 (data not shown). 
DISCUSSION
The BACE-1 transcript leader is long and highly conserved among various mammalian species, two features that are strongly suggestive of a translational control of protein expression. By working with reporter genes, we demonstrate that BACE-1 transcript leader acts as a`silencer' of translation. Since we had previously reported that the level of a toxic protein, called Scamper, is maintained at a low level by an IRES (37), we explored whether this was also the case for BACE-1. The use of the dicistronic approach, an experimental strategy conventionally used to assess the presence of an IRES, did not provide con®rmation for the presence of such a mechanism in the BACE-1 transcript. Rather, we obtained evidence that the inhibition of translation is, at least partially, due to the presence of uATGs. It is known that uATGs can inhibit translation in several ways. When they are recognized by the translation machinery, a futile cycle can occur, so that only the ribosomes skipping the uATG (leaky-scanning) can reach the main ORF. Accordingly, the level of inhibition is directly related to the context for translation initiation: the better an uATG is recognized, the higher is the resulting inhibition (27) . Even in conditions of optimal uATG . Translation driven by BACE-1 transcript leader in resting and activated astrocytes. Astrocytes were transfected in normal culture conditions (resting) or after activation with IL-1b and TNF-a (activated). Transfection was performed with bi-monocistronic plasmids containing either the long (pBRm2L-B1x) or short (pBRm2L-B1y) BACE-1 transcript leader. The increase in Fluc translation between resting and activated astrocytes is also reported (fold increase).
recognition, a small percentage of ribosomes, after translation of the uORF, can continue scanning for start sites (reinitiation), eventually reaching the ATG of the main ORF (43, 44) . Moreover, some peptides produced by translation of a uORF have been reported to interact with the ribosome, further diminishing the ef®ciency of protein translation (45±48). In the case of BACE-1, the second uATG is ef®ciently recognized by the ribosome. However, the presence of another ATG as the last codon before termination in the 72 nt uORF made it impossible to discriminate between leaky scanning and a reinitiation mechanism. We cannot provide conclusive evidence whether complete translation of this uORF occurs and has relevance to the process. Since the recognition of start sites can be modulated, the presence of uATGs might provide a way to regulate protein expression. For instance, phosphorylation of the eukaryotic initiation factor eIF2-a is known to decrease the ef®ciency of ATG recognition with ensuing inhibition of the translation of most transcripts (49) . However, translation of uATG-containing transcripts is paradoxically increased because more ribosomes overcome uATGs and become available for the translation of the main ORF (50) . According to this view, BACE-1 translation might increase in conditions that favour eIF2-a phosphorylation.
The discovery that BACE-1 transcript leader can be alternatively spliced provides an additional possibility for the regulation of BACE-1 expression. In fact, the alternative splicing we describe here reduces the number of uATGs (from 4 to 1) and, as expected, increases the ef®ciency of translation of reporter genes. By RNase protection and RT±PCR we show that this splicing occurs in exocrine pancreas and neuroblastoma cells, but not in normal human brain. Therefore, BACE-1 expression is likely to be affected by changes in the ef®ciency of this splicing event and this might play a role under different physiological as well as pathological conditions.
Although it has long been assumed that the toxic A-b peptide is produced by neurons, the possibility that astrocytes can contribute to this process is gaining momentum (51, 52) . Noticeably, in astrocytes from either AD patients or the Tg2576 transgenic mouse model, BACE-1 protein expression was found only around amyloid plaques, where reactive astrocytes are likely to be present (17, 51) . The current view is that astrocytes do not express BACE-1Ðand thus do not produce A-bÐunless they are brought to a state of chronic activation or they are put in culture (51) . Nothing is known about the switch to promote BACE-1 expression. Transcriptional mechanisms are likely to be involved, but we provide evidence that translational regulation can contribute as well. Our data clearly show that when astrocytes are activated by chronic exposure to cytokines in culture, a marked reduction in the inhibition of translation driven by the BACE-1 transcript leader is recorded. This mechanism is independent of the splicing event described above, since it was observed with both splice variants when transient transfection of reporter genes was performed with the RNA-T7pol vaccinia system, i.e. under conditions that bypass nuclear processing of the transcripts. Interestingly, translation driven by the BACE-1 transcript leader in activated astrocytes reaches an ef®ciency that is similar to that obtained in neurons. This increase has been observed during a process of chronic activation, which also occurs in vivo, while acute activation with physiological stimuli failed to reproduce the effect. In our conditions, the most likely explanation of this effect resides in a variation in translation ef®ciency. We cannot exclude that variations in transcript stability may contribute. However, this clearly shows that after astrocyte activation a non-transcriptional effect on BACE-1 protein production operates.
In conclusion, we provide evidence that BACE-1 expression is inhibited at the translational level by the presence of uATGs. Furthermore, we report that splicing of the transcript leader can change the number of uATGs that are present, thereby providing an additional mechanism for the control. Finally, we show that a release of the inhibition of translation occurs in activated astrocytes, potentially contributing to A-b production. Therefore, even though it is known that BACE-1 can also act on substrates other than APP (53), our ®ndings provide a possible explanation of why in brain tissue of AD patients an increase in BACE-1 protein or activity does not require an increase in BACE-1 mRNA or in the ratio between a-and b-secretase mRNAs (21, 22, 23) , and why changes in BACE-1 mRNA have never been observed around amyloid plaques in transgenic Tg2576 mice (16) .
